Ibrutinib Monotherapy Yields Decade-Long Durable Efficacy in Across CLL Subtypes
Ibrutinib monotherapy produced durable efficacy over 10 years in patients with or without TP53-mutated chronic lymphocytic leukemia.
source
Reporting by onclive. The original article may no longer be reachable at its published URL.
read at onclive ↗
comments(0)
5-min edit window · permanent after that